NASDAQ:SPRB
Spruce Biosciences, Inc.
Spruce Biosciences, Inc.'s revenue fell 100.0% in fiscal 2025 to $0. The diluted share count rose 39.3%.Summary generated from Spruce Biosciences, Inc.'s SEC filings. Latest annual report filed Mar 9, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$0
Revenue growth−100.0%
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−109.2%
Debt / equity0.00
Free cash flown/a
FCF marginn/a
Share count change+39.3%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | n/a | 0 | 10 | 5 | 0 |
| Operating income | −42 | −47 | −52 | −56 | −37 |
| Net income | −42 | −46 | −48 | −53 | −39 |
| Free cash flow | −36 | −42 | −33 | −56 | n/a |
Recent filings
- 10-QQuarterly report for the period ended Jun 30, 2026
Aug 12, 2026 - 8-KResults of operations and financial condition
Aug 12, 2026 - 4Insider transaction report
Jul 29, 2026 - 8-KDirector or officer change
Jul 27, 2026 - 4Insider transaction report
Jul 9, 2026 - 8-KResults of a shareholder vote
May 26, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 13, 2026 - 8-KResults of operations and financial condition
May 13, 2026